News Home

Where Will Pfizer Inc. (PFE) Stock Go Next After It Has Fallen 0.32% in a Week?

Tuesday, August 16, 2022 11:05 AM | InvestorsObserver Analysts
Where Will Pfizer Inc. (PFE) Stock Go Next After It Has Fallen 0.32% in a Week?

The market has been neutral on Pfizer Inc. (PFE) stock recently. PFE gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,neutral
Pfizer Inc. has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on PFE!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With PFE Stock Today?

Pfizer Inc. (PFE) stock is trading at $49.62 as of 11:02 AM on Tuesday, Aug 16, a decline of -$0.13, or -0.26% from the previous closing price of $49.75. The stock has traded between $49.36 and $49.80 so far today. Volume today is light. So far 3,398,740 shares have traded compared to average volume of 18,090,467 shares. To screen for more stocks like Pfizer Inc. click here.

More About Pfizer Inc.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. Click Here to get the full Stock Report for Pfizer Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App